[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R: Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant; 2000 May;25(10):1021-8
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
  • Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML).
  • Allogeneic transplantation (alloSCT) is a therapeutic option.
  • However, it is associated with a high incidence of transplant-related organ toxicity and mortality.
  • We recently reported fast engraftment and minimal transplant-related toxicity, using fludarabine-based conditioning with reduced amounts of chemotoxic drugs prior to alloSCT.
  • Four patients developed >grade II graft-versus-host disease (GVHD).
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Hematopoietic Stem Cell Transplantation. Immunosuppressive Agents / administration & dosage. Lymphoma / therapy. Salvage Therapy. Transplantation Conditioning / methods. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Antilymphocyte Serum / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Busulfan / administration & dosage. Disease-Free Survival. Female. Graft Survival. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Humans. Infection / etiology. Infection / mortality. Life Tables. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / radiotherapy. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Survival Analysis. Transplantation, Homologous / adverse effects. Transplantation, Homologous / mortality. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10828860.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Antimetabolites, Antineoplastic; 0 / Immunosuppressive Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


2. Campanini A, Marani M, Mastroianni A, Cancellieri C, Vicini C: Human immunodeficiency virus infection: personal experience in changes in head and neck manifestations due to recent antiretroviral therapies. Acta Otorhinolaryngol Ital; 2005 Feb;25(1):30-5
Hazardous Substances Data Bank. DIDEOXYINOSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus infection: personal experience in changes in head and neck manifestations due to recent antiretroviral therapies.
  • Both the incidence and prevalence of human immunodeficiency virus infection are increasing in the world.
  • The otorhinolaryngological manifestations in association with HIV infection are mainly atypical, so common in the clinical practice, really aspecific and very frequent in ENT daily routine (such as sinusitis, otitis, etc.) and, therefore, immunodeficiency may not be suspected.
  • In other cases, ENT evidence is more peculiar or unusual, such as opportunistic infections, rare neoplasm and tumours with an unusual course, giving a very high suspect of a human immunodeficiency virus-related infection.
  • The most frequent malignant neoplasm is Kaposi's Sarcoma which is extremely rare in non-human immunodeficiency virus-infected subjects; the second most frequent is non-Hodgkin's lymphoma with 50% in extranodal sites (oral and maxillary sinus).
  • Following a review of the literature, modifications caused by current antiretroviral treatment on head and neck manifestations of human immunodeficiency virus infection have been evaluated.
  • Highly active antiretroviral therapy is a new therapeutic strategy, based on poly-chemo-therapeutic schemes, providing simultaneously two or more anti-retroviral drugs.
  • We have used highly active antiretroviral therapy in human immunodeficiency virus infection since 1997, substituting previous mono-chemotherapy based on Zidovudine or Didanosine alone.
  • Highly active antiretroviral therapy is extremely efficient in reducing the viral load of human immunodeficiency virus and increasing CD4+ T-lymphocyte count.
  • To evaluate the effects of highly active antiretroviral therapy on otorhinolaryngological manifestations in human immunodeficiency virus infection, we performed a retrospective study on 470 adults, observed over 14 years (1989-2002) and constantly receiving the same treatment, with follow-up from 7 to 80 months.
  • A total of 250 subjects underwent mono-antiretroviral chemotherapy (1989-1996), while 220 underwent highly active antiretroviral therapy (1997-2002).
  • The results of the retrospective study showed that highly active antiretroviral therapy has greatly improved the control of the immune-deficiency (increasing the range of CD4+), reducing the number of otorhinolaryngological manifestations (also tumours).
  • On the other hand, 2 patients presented sudden unilateral hearing loss following treatment: toxicity due to association of new drugs cannot be excluded.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. HIV Infections / drug therapy. HIV Infections / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Sarcoma, Kaposi / epidemiology
  • [MeSH-minor] Adult. Antigens, CD4 / immunology. Didanosine / therapeutic use. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Incidence. Male. Prevalence. Pseudomonas Infections / epidemiology. Zidovudine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Otorrinolaringol Esp. 2000 Mar;51(2):169-73 [10804122.001]
  • [Cites] Rhinology. 1999 Jun;37(2):93-5 [10416258.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 2002;123(4):231-4 [12723487.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2003 Jun;28(3):240-3 [12755764.001]
  • [Cites] J Indian Med Assoc. 2003 Feb;101(2):93-5 [12841491.001]
  • [Cites] J Laryngol Otol. 1990 Jan;104(1):58-60 [2313182.001]
  • [Cites] Acta Otorrinolaringol Esp. 1990 Sep-Oct;41(5):277-80 [2076306.001]
  • [Cites] An Otorrinolaringol Ibero Am. 1991;18(2):157-68 [2053696.001]
  • [Cites] Acta Otorhinolaryngol Ital. 1992 Mar-Apr;12(2):107-17 [1414319.001]
  • [Cites] Ann R Coll Surg Engl. 1993 Nov;75(6):417-21 [8054007.001]
  • [Cites] Acta Otorrinolaringol Esp. 1993 Nov-Dec;44(6):467-70 [8155366.001]
  • [Cites] Allergol Immunopathol (Madr). 1994 Sep-Oct;22(5):192-6 [7840019.001]
  • [Cites] An Otorrinolaringol Ibero Am. 1995;22(2):139-49 [7778717.001]
  • [Cites] Bull Soc Pathol Exot. 1995 Apr;88(5):234-5 [8646013.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1996 Feb;21(1):30-6 [8674220.001]
  • [Cites] Acta Otorrinolaringol Esp. 1996 Jul-Aug;47(4):311-3 [8962735.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1996;113(2):69-72 [8999746.001]
  • [Cites] Acta Otorrinolaringol Esp. 1997 Jan-Feb;48(1):27-30 [9131922.001]
  • [Cites] Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1997 Feb;11(2):64-5 [9644183.001]
  • [Cites] Int J Clin Pract. 1998 Apr-May;52(3):141-4 [9684426.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1998 Jul 10;44(2):103-7 [9725525.001]
  • [Cites] Presse Med. 1999 Apr 17;28(15):809-14 [10325941.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1999 Jun;116(3):149-53 [10399530.001]
  • [Cites] Vestn Otorinolaringol. 2002;(1):4-6 [11892394.001]
  • (PMID = 16080313.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD4; 4B9XT59T7S / Zidovudine; K3GDH6OH08 / Didanosine
  • [Other-IDs] NLM/ PMC2639849
  •  go-up   go-down


3. Roilides E, Lamaignere CG, Farmaki E: Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy. Int J Infect Dis; 2002 Sep;6(3):154-63
MedlinePlus Health Information. consumer health - Fungal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy.
  • A number of cytokines have been developed and studied in vitro for activity against fungal pathogens.
  • The fields where these cytokines have been predominantly studied or where they may need more study are primary immunodeficiencies of the phagocytic cells, neonatal age, human immunodeficiency virus infection and cancer-related conditions such as neutropenia and hemopoietic cell transplantation.
  • [MeSH-major] Cytokines / therapeutic use. Immunocompromised Host. Mycoses / drug therapy. Mycoses / immunology
  • [MeSH-minor] Adolescent. Animals. Aspergillosis / drug therapy. Aspergillosis / immunology. Candidiasis / drug therapy. Candidiasis / immunology. Humans. Male. Mice

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12718828.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 95
  •  go-up   go-down


Advertisement
4. Mundhenke C, Bauerschlag D, Fischer D, Friedrich M, Maass N: [Malignant tumors of the uterus]. Ther Umsch; 2007 Jul;64(7):381-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant tumors of the uterus].
  • [Transliterated title] Maligne Tumoren des Uterus.
  • Malignant uterine tumors are responsible for up to 9% of all new cancer cases and for 4.5% of all cancer related deaths in women.
  • Endometrial cancers are typically found in elderly women and are > 70% hormone sensitive (type I), type II is often less differentiated and not hormone sensitive.
  • Therapy of choice is the stage related radical hysterectomy (incl. lymphnode dissection).
  • Postoperatively and at progressive stages endocrine and radiation therapies can be useful.
  • Chemotherapy is only useful in not hormone sensitive and in progressive tumors.
  • These often aggressive tumors are hardly responding to systemic and radiation therapy.
  • Therefore radical tumor surgery plays the main therapeutic role.
  • Cervical carcinomas are usually growing on an underlying chronic infection with oncogenic HPV subtypes.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cervix Uteri / pathology. Combined Modality Therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / epidemiology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Endometrium / pathology. Female. Humans. Hysterectomy. Hysteroscopy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Postoperative Care. Risk Factors. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948755.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 36
  •  go-up   go-down


5. Konstantinopoulos PA, Sullivan RJ, Karamouzis MV, Dezube BJ: Investigational agents for treatment of AIDS-related Kaposi's sarcoma. Expert Opin Investig Drugs; 2007 Apr;16(4):495-504
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigational agents for treatment of AIDS-related Kaposi's sarcoma.
  • AIDS-related Kaposi's sarcoma (KS) is a neoplasm that results from the co-infection of HIV and KS herpesvirus/human herpesvirus-8 (KSHV/HHV8).
  • Targeting HIV with highly active antiretroviral therapy has attenuated the natural history of this disease.
  • Recent discoveries have elucidated the role of multiple signaling pathways in the pathogenesis of AIDS-related KS.
  • In addition, KSHV/HHV8 can modulate cellular growth and angiogenic pathways to augment malignant transformation and potentiate growth.
  • This article discusses the main signaling pathways that are implicated in the pathogenesis of AIDS-related KS, reviews recently completed clinical trials and anticipates the future direction of molecularly targeted agents in this disease.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antiviral Agents / therapeutic use. Drugs, Investigational / therapeutic use. Sarcoma, Kaposi / drug therapy


6. Angulo-Pernett F, Smythe WR: Primary lymphoepithelioma of the esophagus. Ann Thorac Surg; 2003 Aug;76(2):603-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This very rare Epstein-Barr virus infection-related malignancy has previously been reported only in patients from Japan.
  • The tumor exhibited classic histologic and immunohistochemical features of lymphoepithelioma, and was successfully treated with neoadjuvant chemotherapy and irradiation followed by surgical resection.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Esophagectomy / methods. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12902114.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Cohen MH, Gootenberg J, Keegan P, Pazdur R: FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist; 2007 Jun;12(6):713-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
  • Food and Drug Administration granted approval for bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA), administered in combination with carboplatin and paclitaxel, for the initial treatment of patients with unresectable, locally advanced, recurrent, or metastatic, nonsquamous, non-small cell lung cancer (NSCLC).
  • A randomized, open label, multicenter clinical trial, conducted by the Eastern Cooperative Oncology Group (ECOG), in chemotherapy-naïve patients with stage IIIB/IV nonsquamous NSCLC, evaluated bevacizumab plus carboplatin and paclitaxel (BV/CP, n = 434) versus carboplatin and paclitaxel alone (CP, n = 444).
  • Among the 878 randomized patients, the median age was 63, 46% were female, 76% had stage IV disease, 12% had stage IIIB disease with malignant pleural effusion, 11% had recurrent disease, and 40% had an ECOG performance status score of 0.
  • Severe and life-threatening adverse events occurring more frequently in patients receiving BV/CP were neutropenia (27% versus 17%), fatigue (16% versus 13%), hypertension (8% versus 0.7%), infection without neutropenia (7% versus 3%), thrombosis/embolism (5% versus 3%), pneumonitis or pulmonary infiltrate (5% versus 3%), infection with grade 3 or 4 neutropenia (5% versus 2%), febrile neutropenia (5% versus 2%), hyponatremia (4% versus 1%), proteinuria (3% versus 0), and headache (3% versus 0.5%).
  • Fatal, treatment-related adverse events in patients receiving bevacizumab were pulmonary hemorrhage (2.3% versus 0.5%), gastrointestinal hemorrhage, central nervous system infarction, gastrointestinal perforation, myocardial infarction, and neutropenic sepsis.
  • The most common adverse events in patients receiving bevacizumab are asthenia, pain, abdominal pain, headache, hypertension, diarrhea, nausea, vomiting, anorexia, stomatitis, constipation, upper respiratory infection, epistaxis, dyspnea, exfoliative dermatitis, and proteinuria.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Carboplatin / administration & dosage. Carboplatin / adverse effects. Drug Approval. Headache / chemically induced. Humans. Middle Aged. Multicenter Studies as Topic. Neoplasm Metastasis. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Pain / chemically induced. Randomized Controlled Trials as Topic. Treatment Outcome. United States. United States Food and Drug Administration. Vomiting / chemically induced


8. Di Piazza M, Mader C, Geletneky K, Herrero Y Calle M, Weber E, Schlehofer J, Deleu L, Rommelaere J: Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol; 2007 Apr;81(8):4186-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are often resistant to the induction of apoptotic cell death as a result of the development of survival mechanisms during astrocyte malignant transformation.
  • In vivo, parvovirus H-1 infection of rat glioma cells intracranially implanted into recipient animals triggers cathepsin B activation as well.
  • This report identifies for the first time cellular effectors of the killing activity of parvovirus H-1 against malignant brain cells and opens up a therapeutic approach which circumvents their frequent resistance to other death inducers.
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Astrocytes / virology. Brain Neoplasms / enzymology. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Brain Neoplasms / virology. Cathepsin L. Cisplatin / pharmacology. Cystatin B. Cystatin C. Cystatins / metabolism. Cytosol / enzymology. Disease Models, Animal. Drug Resistance, Neoplasm. Enzyme Activation. Humans. Lysosomes / enzymology. Oncolytic Virotherapy. Rats. Rats, Inbred WKY. Recombinant Proteins / pharmacology. TNF-Related Apoptosis-Inducing Ligand / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virus Res. 1999 Dec 15;65(2):161-74 [10581389.001]
  • [Cites] Scand J Infect Dis. 2004;36(8):570-7 [15370668.001]
  • [Cites] J Virol. 1974 Oct;14(4):791-801 [4278742.001]
  • [Cites] Nucleic Acids Res. 1980 Sep 11;8(17):3993-4007 [6777759.001]
  • [Cites] J Virol Methods. 1991 Aug;33(3):233-51 [1783673.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6027-31 [7954439.001]
  • [Cites] EMBO J. 1996 Aug 1;15(15):3861-70 [8670891.001]
  • [Cites] Science. 1997 Aug 8;277(5327):815-8 [9242610.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1675-87 [9501089.001]
  • [Cites] J Virol. 1998 Nov;72(11):8893-903 [9765434.001]
  • [Cites] Curr Opin Immunol. 1998 Oct;10(5):545-51 [9794832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):192-7 [15618392.001]
  • [Cites] J Cell Sci. 2005 Jan 15;118(Pt 2):265-7 [15654015.001]
  • [Cites] J Pathol. 2005 Jan;205(2):275-92 [15641020.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):1008-15 [16153465.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17148-53 [16284249.001]
  • [Cites] Cell Tissue Res. 2006 Sep;325(3):423-36 [16699801.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Mar;132(3):171-83 [16362335.001]
  • [Cites] Lab Invest. 1999 Dec;79(12):1573-82 [10616207.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Arch Biochem Biophys. 2000 Mar 15;375(2):347-54 [10700391.001]
  • [Cites] J Clin Invest. 2000 Nov;106(9):1127-37 [11067865.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1162-70 [11221847.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2878-84 [11306462.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1063-75 [11314043.001]
  • [Cites] Cancer Gene Ther. 2001 Mar;8(3):158-67 [11332986.001]
  • [Cites] Biochem J. 2001 Jun 1;356(Pt 2):549-55 [11368784.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):999-1010 [11381085.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Mutat Res. 2001 Jul 1;478(1-2):23-43 [11406167.001]
  • [Cites] Oncogene. 2001 Jun 21;20(28):3665-73 [11439329.001]
  • [Cites] Dev Cell. 2001 Aug;1(2):291-302 [11702787.001]
  • [Cites] FEBS Lett. 2001 Dec 14;509(3):399-404 [11749963.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6286-91 [11959917.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25020-5 [11976344.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] J Virol. 2003 Mar;77(6):3851-8 [12610161.001]
  • [Cites] Glia. 2003 Apr 15;42(2):194-208 [12655603.001]
  • [Cites] EMBO J. 2003 Oct 1;22(19):5313-22 [14517268.001]
  • [Cites] Cell Death Differ. 2003 Nov;10(11):1253-9 [14576777.001]
  • [Cites] Virology. 2003 Nov 25;316(2):267-80 [14644609.001]
  • [Cites] Int J Cancer. 2004 Mar10;109(1):76-84 [14735471.001]
  • [Cites] Cell. 2004 Jan 23;116(2):205-19 [14744432.001]
  • [Cites] Biochem J. 2004 Mar 15;378(Pt 3):705-16 [14705960.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2881-90 [15077151.001]
  • [Cites] Annu Rev Biochem. 2004;73:87-106 [15189137.001]
  • [Cites] J Mol Biol. 1967 Jun 14;26(2):365-9 [4291934.001]
  • (PMID = 17287256.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CST3 protein, human; 0 / CSTB protein, human; 0 / Cst3 protein, rat; 0 / Cystatin C; 0 / Cystatins; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 88844-95-5 / Cystatin B; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L; EC 3.4.22.15 / Ctsl protein, rat; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC1866092
  •  go-up   go-down


9. Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM: Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol; 2005 May 20;23(15):3495-501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
  • PURPOSE: To determine pathologic response rates to liposome-entrapped cis-bisneodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma.
  • PATIENTS AND METHODS: Thirty-three patients with malignant pleural mesothelioma and free-flowing pleural effusions received intrapleural L-NDDP once every 3 weeks at a dose of 450 mg/m2.
  • Thoracoscopic evaluation with pleural biopsies was performed before therapy and then after every two cycles.
  • RESULTS: After at least two cycles, post-treatment pleural biopsy analysis was negative in 14 patients for a pathologic response rate of 42% (95% CI, 25% to 61%).
  • There were three treatment-related deaths secondary to peritonitis, cellulitis at the thoracoscopy site, and empyema.
  • Grade 3 nonhematologic toxicities included infection, fever, dyspnea, and anorexia, which occurred in five (15%), one (3%), one (3%), and one (3%) patients, respectively.
  • CONCLUSION: Intrapleural L-NDDP therapy in this patient population is feasible with significant but manageable toxicity.
  • Although pathologic responses are highly encouraging, areas of mesothelioma that are not in direct communication with the pleural space will evade drug exposure and limit efficacy in some patients.
  • The optimal role of intrapleural L-NDDP therapy currently remains to be determined.
  • [MeSH-major] Mesothelioma / drug therapy. Mesothelioma / pathology. Organoplatinum Compounds / administration & dosage. Pleural Neoplasms / drug therapy. Pleural Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Chemotherapy, Cancer, Regional Perfusion. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Carriers. Female. Follow-Up Studies. Humans. Immunohistochemistry. Liposomes. Male. Middle Aged. Neoplasm Staging. Probability. Risk Assessment. Survival Rate. Thoracoscopy. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908659.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / FDA HHS / FD / FD-R-00167; United States / NCI NIH HHS / CA / K12 CA088084
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 0 / Organoplatinum Compounds; 113427-19-3 / bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II)
  •  go-up   go-down


10. Längler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F: Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study. Klin Padiatr; 2002 Jul-Aug;214(4):153-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study.
  • BACKGROUND: The topoisomerase-I-inhibitor Topotecan (TPT) has shown a broad activity in the therapy of adult malignant diseases.
  • METHODS: From 1/98 to 8/99 we conducted a multicenter phase-II-study of TPT (1.5 mg/m (2)/d in 30 min i. v. for 5 days every 21 days) in pediatric patients (pts) with malignant tumors refractory to conventional therapy (either second line or any relapse).
  • The 7 female and 13 male pts had a median age of 10.2 years at the beginning of the TPT therapy.
  • For all study-pts the median overall survival time was 235 days with 1 pt. still alive.
  • Non-hematologic toxicity was mild with the exception of 4 cycles with infection grade III and 1 grade IV.
  • No patient died of therapy-related complications.
  • Further evaluation of TPT treatment is planned using combinations with other cytostatic drugs.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Neoplasms / drug therapy. Neuroblastoma / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infant. Male. Neoplasm Staging. Quality of Life. Survival Rate. Treatment Outcome


11. Thiede C, Wündisch T, Alpen B, Neubauer B, Morgner A, Schmitz M, Ehninger G, Stolte M, Bayerdörffer E, Neubauer A, German MALT Lymphoma Study Group: Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol; 2001 Mar 15;19(6):1600-9
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma.
  • PURPOSE: Cure of Helicobacter pylori infection is associated with remission induction in the majority of patients with low-grade gastric mucosa associated lymphoid tissue (MALT) lymphoma in localized stages; however, limited data exist as to whether these patients may be cured of their lymphoma.
  • PATIENTS AND METHODS: Ninety-seven patients who suffered from low-grade gastric MALT lymphoma stage I(E) were observed with central pathology and molecular biology after cure of H pylori infection.
  • Twenty of 44 patients with PCR monoclonality at diagnosis and with sufficient molecular follow-up displayed monoclonal bands for a median time of 20.5 months after CR (range, 0 to 50.4 months).
  • These B cells were related to the original lymphoma clone by sequence analysis.
  • All four patients displayed monoclonal PCR before relapse, and three of these four showed ongoing PCR monoclonality throughout their course, indicating the persistence of malignant cells.
  • CONCLUSION: Half of all patients with gastric MALT lymphoma show long-term PCR monoclonality up to several years after cure of H pylori infection and CR.
  • [MeSH-major] B-Lymphocytes / immunology. DNA, Neoplasm / analysis. Helicobacter Infections / drug therapy. Helicobacter pylori / pathogenicity. Lymphoma, B-Cell, Marginal Zone / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Survival. Clone Cells. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Prospective Studies. Sequence Analysis, DNA. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11250988.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


12. Muscolo DL, Ayerza MA, Aponte-Tinao L, Ranalletta M, Abalo E: Intercalary femur and tibia segmental allografts provide an acceptable alternative in reconstructing tumor resections. Clin Orthop Relat Res; 2004 Sep;(426):97-102
MedlinePlus Health Information. consumer health - Bone Grafts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intercalary femur and tibia segmental allografts were implanted in 59 consecutive patients after segmental resection-52 for malignant and seven for benign aggressive bone tumors.
  • Infection, fracture, and nonunion rates were determined.
  • The overall 5-year survivorship for the 59 intercalary allografts was 79%, and we found no significant differences between allograft survival in patients receiving or not receiving adjuvant chemotherapy.
  • Infection and fracture rates were 5% and 7% respectively.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Graft Survival. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Reoperation. Survival Analysis. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15346058.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Mousset S, Hermann S, Klein SA, Bialleck H, Duchscherer M, Bomke B, Wassmann B, Böhme A, Hoelzer D, Martin H: Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol; 2005 Oct;84(11):734-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with haematological malignancies and prolonged periods of neutropenia after chemotherapy are at high risk for severe bacterial and fungal infections.
  • Those infections have long time been considered as a contraindication for subsequent haematopoietic stem cell transplantation (HCT).
  • We conducted a prospective, non-randomized study of granulocyte transfusions (GTX) to control acute life-threatening infections (44 episodes) and to prevent recurrence of severe fungal infections during HCT or intensive chemotherapy (23 episodes).
  • No single reactivation of a previous infection occurred under prophylactic GTX (0/23).
  • Median survival was 170 days in the interventional group and 185 days in the prophylactic group; death in both patient groups was mainly due to underlying progressive malignant disease.
  • We conclude that under GTX, the infection-related mortality even in high-risk patients is low.
  • [MeSH-major] Granulocytes / transplantation. Hematologic Neoplasms / therapy. Leukocyte Transfusion. Neutropenia / therapy
  • [MeSH-minor] Adult. Aged. Blood Group Incompatibility. Blood Transfusion. Critical Care. Female. Humans. Leukemia / blood. Leukemia / pathology. Leukemia / therapy. Living Donors. Lymphoma / blood. Lymphoma / pathology. Lymphoma / therapy. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951986.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


14. Jung JI, Kim HH, Park SH, Song SW, Chung MH, Kim HS, Kim KJ, Ahn MI, Seo SB, Hahn ST: Thoracic manifestations of breast cancer and its therapy. Radiographics; 2004 Sep-Oct;24(5):1269-85
MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracic manifestations of breast cancer and its therapy.
  • Breast cancer is the second most common cause of cancer-related death in women.
  • In most patients, imaging demonstrates thoracic changes resulting from either treatment, complications of treatment, or tumor recurrence or metastasis.
  • The most common surgery-related complication is seroma.
  • Radiation therapy frequently causes radiation pneumonitis, which occurs approximately 4-12 weeks after the completion of therapy and is characteristically limited to the field of irradiation.
  • Chemotherapy-related complications include cardiotoxicity, pneumonitis, and infection.
  • Ultrasonography and computed tomography are more sensitive than physical examination for detecting local and regional recurrence.
  • Familiarity with the spectrum of radiologic findings in breast cancer patients allows accurate image interpretation and correct diagnosis.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Artifacts. Female. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis / radiography. Mammaplasty. Mastectomy / adverse effects. Mastectomy / methods. Middle Aged. Neoplasm Recurrence, Local / radiography. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / radiography. Pneumonia / chemically induced. Pneumonia / radiography. Postoperative Complications / etiology. Postoperative Complications / radiography. Radiation Injuries / radiography. Radiotherapy / adverse effects. Seroma / radiography. Spinal Cord Compression / etiology. Spinal Cord Compression / radiography. Spinal Neoplasms / radiography. Spinal Neoplasms / secondary. Thoracic Neoplasms / radiography. Thoracic Neoplasms / secondary. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2004
  • [ErratumIn] Radiographics. 2004 Nov-Dec;24(6):1610
  • (PMID = 15371608.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


15. Maisch B, Ristic A, Pankuweit S: Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis; 2010 Sep-Oct;53(2):157-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a considerable number of patients with breast or lung cancer or with mediastinal lymphoma, in addition to direct involvement by the tumor, radiation therapy as well as systemic tumor treatment can also lead to pericardial effusion.
  • We collected prospectively but analyzed retrospectively 357 patients undergoing pericardiocentesis from 1988 to 2008 and identified 68 patients who had cancer-related pericardial effusion.
  • With these methods, 42 patients demonstrated malignant effusion, 15 patients had radiation-induced pericardial, effusion, and in 11 patients without radiation therapy, the effusion could be attributed to either viral infection in 5 cases or to an autoimmune process in the remaining 6 patients.
  • Consequently, intrapericardial treatment could be tailored for each cohort: neoplastic effusion was treated with intrapericardial cisplatin (single instillation of 30 mg/m(2) per 24 hours); in addition to the tumor-specific systemic chemotherapy, intrapericardial triamcinolone acetate (Volon A) was given in a dose of 500 mg/m(2) in the patients with autoimmune and radiation-induced effusion.
  • Saline rinsing and intrapericardial sclerosing treatment were the treatment of choice in viral pericardial effusion.
  • Oral colchicine treatment (2-3 x 0.5 mg) was given in all patients for at least 3 months.
  • This differential diagnostic approach and the results of treatment were compared with published series.
  • [MeSH-major] Neoplasms / therapy. Pericardial Effusion / diagnosis. Pericardial Effusion / therapy. Radiation Injuries / diagnosis. Radiation Injuries / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Bacterial Infections / complications. Biomarkers / analysis. Biopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pericardiocentesis. Polymerase Chain Reaction. Predictive Value of Tests. Radiotherapy / adverse effects. Recurrence. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Virus Diseases / complications

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20728703.001).
  • [ISSN] 1873-1740
  • [Journal-full-title] Progress in cardiovascular diseases
  • [ISO-abbreviation] Prog Cardiovasc Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers
  •  go-up   go-down


16. Ravandi F, O'Brien S: Alemtuzumab. Expert Rev Anticancer Ther; 2005 Feb;5(1):39-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alemtuzumab is a humanized monoclonal antibody against CD52, a small glycosylphosphatidylinositol-anchored glycoprotein that is highly expressed on normal T- and B-lymphocytes, and on a large proportion of malignant lymphoid cells, but not on hematopoietic progenitor cells.
  • Over the past several years, a number of clinical trials have demonstrated the clinical activity of alemtuzumab in treating patients with chronic lymphocytic leukemia, T-cell malignancies such as T-prolymphocytic leukemia and cutaneous T-cell lymphoma, as well as in the prevention and therapy of graft-versus-host disease in the setting of allogeneic stem cell transplantation.
  • The most significant side effect of alemtuzumab is predisposition to infections related to the associated profound lymphopenia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Autoimmune Diseases / drug therapy. Hematologic Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antigens, CD / immunology. Antigens, Neoplasm / immunology. Clinical Trials as Topic. Glycoproteins / immunology. Humans. Infection / chemically induced

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757437.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Number-of-references] 91
  •  go-up   go-down


17. Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC: Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol; 2003 Apr;89(1):16-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The principles of cytoreduction before chemotherapy suggest that resection of measurable liver lesions in properly selected patients would be beneficial.
  • To determine the effect of resection of metachronous liver metastases on morbidity and survival, we reviewed our experience with this treatment.
  • METHODS: Medical records were reviewed retrospectively for all patients who had anatomic hepatic resection for metachronous parenchymal liver metastases from ovarian carcinoma (epithelial or malignant mixed Müllerian tumors) at Mayo Clinic from 1976 to 1999.
  • Aside from blood loss requiring transfusion of more than 4 units of erythrocytes in 4 patients, only two complications were noted: one superficial wound infection and one small-bowel perforation that required reoperation.
  • The overall median disease-related survival was 26.3 months after hepatic resection; 18 patients (69%) died of disease at a median of 14.6 months (range, 5.0-41.3 months).
  • Factors significantly associated with improved disease-related survival were consistent with known prognostic factors associated with cytoreductive surgery, including more than 12 months since original diagnosis (27.3 vs 5.7 months, P = 0.004) and less than or equal to 1 cm of residual disease after hepatic resection (27.3 vs 8.6 months, P = 0.031).
  • Because of the disease-related survival advantage afforded women by optimal cytoreductive surgery, parenchymal liver metastases should not preclude secondary cytoreductive surgical efforts.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / secondary. Neoplasms, Second Primary / surgery. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694649.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Merimsky O, Kollender Y, Inbar M, Lev-Chelouche D, Gutman M, Issakov J, Mazeh D, Shabat S, Bickels J, Meller I: Is forequarter amputation justified for palliation of intractable cancer symptoms? Oncology; 2001;60(1):55-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is forequarter amputation justified for palliation of intractable cancer symptoms?
  • Amputation has been advocated as a palliative procedure for symptomatic locally advanced disease that has already failed to respond to radiation therapy, chemotherapy and limited surgery.
  • METHODS: Twelve patients with advanced malignant tumors involving the shoulder girdle or the proximal humerus underwent forequarter amputation (FQA) for palliative purposes.
  • The tumor-related local problems were severe pain, limb dysfunction, tumor fungation, bleeding (requiring emergency FQA in one case) and infection.
  • Survival was measured in months (3-24 months), but ultimately had no meaning since the procedure was palliative.
  • [MeSH-major] Amputation / methods. Arm / surgery. Neoplasm Recurrence, Local / surgery. Palliative Care / methods. Quality of Life. Shoulder / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11150909.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. López-Gómez JM, Portolés JM, Aljama P: Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl; 2008 Dec;(111):S75-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The response to erythropoietin-stimulating agents (ESA) can vary among different patients and according to the different circumstances over time within a given individual.
  • To evaluate the dose-response effect of EPO therapy, we used the erythropoietin resistance index (ERI), calculated as the weekly weight-adjusted dose of EPO divided by the hemoglobin level.
  • ERI was directly related with incident comorbidity (Charlson Index), age, female gender and low body mass index with no relationship with etiology of chronic kidney disease.
  • Patients with antecedents of heart failure, acute infection or malignant neoplasm had significantly higher ERI than those without.
  • Transferrin saturation index, but not serum ferritin, was inversely related with ERI.
  • Serum levels of albumin and cholesterol were related with lower ERI, but no relation was found with normalized protein catabolic rate.
  • The resistance to ESA is directly related with incident comorbidity in patients on hemodialysis and it can be interpreted as a useful marker of early mortality.
  • [MeSH-minor] Aged. Biomarkers / blood. Cholesterol / blood. Chronic Disease. Dose-Response Relationship, Drug. Female. Ferritins / blood. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Serum Albumin / metabolism. Spain. Survival Analysis. Transferrin / metabolism

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19034333.001).
  • [ISSN] 0098-6577
  • [Journal-full-title] Kidney international. Supplement
  • [ISO-abbreviation] Kidney Int. Suppl.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Serum Albumin; 0 / Transferrin; 11096-26-7 / Erythropoietin; 9007-73-2 / Ferritins; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


20. Mischke A, Besier S, Walcher F, Waibel H, Brade V, Brandt C: [Spontaneous gas gangrene in a diabetic patient with Clostridium septicum]. Chirurg; 2005 Oct;76(10):983-6
Hazardous Substances Data Bank. CLINDAMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] "Spontaner" Gasbrand mit Kompartmentsyndrom bei einem diabetischen Patienten.
  • Atraumatic infections due to Clostridium septicum are known to be associated with immunosuppression or even malignancy.
  • In this case report, we present a patient with severe Clostridium septicum infection related to advanced colon cancer that had not previously been diagnosed.
  • The case demonstrates the strong association between Clostridium septicum infections and malignancy, particularly in the presence of other predisposing diseases such as diabetes mellitus.
  • It strongly suggests excluding malignant neoplasms, especially of the gastrointestinal tract, when severe Clostridium septicum infections occur.
  • Moreover, if patients with known colorectal or other malignancy develop septicaemia or spontaneous gas gangrene, clinicians should be aware of Clostridium septicum as one of the main causative agents, as early diagnosis and aggressive treatment are important to improve prognosis.
  • [MeSH-major] Adenocarcinoma / complications. Clostridium / isolation & purification. Colonic Neoplasms / complications. Diabetes Mellitus, Type 2 / complications. Gas Gangrene / etiology. Paraneoplastic Syndromes
  • [MeSH-minor] Anti-Bacterial Agents / administration & dosage. Anti-Bacterial Agents / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Clindamycin / administration & dosage. Clindamycin / therapeutic use. Colectomy. Colonoscopy. Debridement. Drug Therapy, Combination. Humans. Liver / pathology. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Penicillins / administration & dosage. Penicillins / therapeutic use. Radiography. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Emerg Med. 2003 May;24(4):401-5 [12745042.001]
  • [Cites] Pol Merkur Lekarski. 2004 Oct;17(100):403-6 [15690715.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):353-6 [10705386.001]
  • [Cites] ANZ J Surg. 2001 Nov;71(11):647-9 [11736823.001]
  • [Cites] Rev Esp Enferm Dig. 2002 Jun;94(6):361-6 [12432593.001]
  • [Cites] Rev Infect Dis. 1990 Mar-Apr;12(2):286-96 [2330482.001]
  • [Cites] Medicine (Baltimore). 1989 Jan;68(1):30-7 [2642585.001]
  • (PMID = 16021394.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Penicillins; 3U02EL437C / Clindamycin
  •  go-up   go-down






Advertisement